A Phase 1 safety study of single-agent immunotherapy drug, Avelumab, combined with stereotactic
body radiation therapy (SBRT) was well-tolerated by mesothelioma patients
with no severe side effects. The study was led by researchers from Memorial
Sloan Kettering Cancer Center in New York and conducted on a small group
of patients who progressed on prior chemotherapy treatment.
Radiation therapy is considered highly effective at precisely targeting
tumors. While monoclonal antibody Avelumab has demonstrated modest efficacy
in mesothelioma. The safety of combining both treatments was previously
unknown. With these findings, researchers will hopefully advance the study
into later phases.
To date, there is still no standard approach for second-line therapy after
initial progression in mesothelioma. Research into second-line therapy
treatments continues to test new therapeutic approaches and show promising results.